Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

NCT06397222 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

DRUG: Sin-Bev-SIRT

Sponsor

Second Affiliated Hospital of Guangzhou Medical University